Teva Pharmaceuticals
Teva Pharmaceuticals is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Teva Pharmaceuticals.
Teva Pharmaceuticals is a company.
Key people at Teva Pharmaceuticals.
Key people at Teva Pharmaceuticals.
Teva Pharmaceutical Industries Ltd. is a global leader in generic and innovative biopharmaceutical medicines, ranking among the top 15-26 largest pharmaceutical companies worldwide.[1][2][3][4][6] Founded over 120 years ago, it develops, manufactures, and distributes affordable generics, specialty drugs, and biologics to patients in 57 markets, supported by 37,000 employees and a network focused on advancing healthcare through innovation and accessibility.[6] Teva serves healthcare providers, pharmacies, and patients by addressing critical needs in areas like neurology, respiratory health, oncology, and women's health, solving the problem of high drug costs via generics while pioneering treatments like multiple sclerosis therapies.[1][2][4]
Teva traces its roots to 1901 in Jerusalem, then part of the Ottoman Empire, when pharmacists Chaim Salomon, Moshe Levin, and Yitschak Elstein founded Salomon, Levin, and Elstein Ltd. (SLE), a small wholesale drug business distributing imported medicines via mule trains and camel caravans.[1][2][3][4][7][8] In the 1930s, amid growing demand for local production, immigrants established related firms like Assia and Zori; SLE spun off Assia, and by 1935, Günther Friedländer and Else Kober formalized Teva Middle East Pharmaceutical & Chemical Works Co. Ltd.[4] Key mergers in 1968 (Assia/Zori acquiring Teva) and 1976 (forming Teva Pharmaceutical Industries Ltd., Hebrew for "nature") under CEO Eli Hurvitz (1976-2002, Chairman until 2010) marked consolidation.[1][2][4] Early traction came from local manufacturing; pivotal global expansion began in the 1980s-2000s via acquisitions like Ikapharm (1980), Plantex (1980), Copley (1999), Sicor (2004), IVAX (2006), Barr (2008), and others, establishing dominance in generics across North America, Europe, and beyond.[1][2][4][5]
Teva rides the trend of healthcare democratization, where generics counter rising drug prices amid aging populations and chronic disease surges, making treatments accessible globally.[1][6] Timing aligns with post-patent cliffs for blockbusters and biosimilars' rise, amplified by market forces like regulatory approvals (e.g., Hatch-Waxman Act favoring generics) and demand in emerging markets.[2][4] It influences the ecosystem by pressuring originators on pricing, fostering competition, and investing in APIs/humanitarian supply, though facing antitrust scrutiny over alleged price-fixing.[4] In pharma's "tech" evolution, Teva leverages digital R&D and biologics to bridge traditional manufacturing with innovative therapies.
Teva's trajectory points to sustained generics dominance with growing biopharma focus, potentially via more biosimilars and CNS therapies amid patent expirations and AI-driven drug discovery.[6] Trends like personalized medicine, supply chain localization post-COVID, and inflation pressures will shape it, evolving its influence toward hybrid generic-innovator models. As a century-old pioneer, Teva remains pivotal in equitable healthcare, scaling from Jerusalem caravans to global leadership.